Selective cytotoxicity against human tumour cells by a vindesine-monoclonal antibody conjugate

Antigenicity and drug susceptibility of human osteogenic sarcoma cells “escaping” a cytotoxic methotrexate-albumin-monoclonal antibody conjugate

“…Several groups have shown that anti-tumour antibodies can be used to direct toxins or therapeutic drugs to appropriate tumour cells and thereby achieve increased cytotoxicity (Ghose & Blair, 1978; Thorpe & Ross, 1982). We have previously reported the selective action in vitro of conjugates of vindesine or methotrexate (MTX) with a monoclonal antibody to a human osteogenic sarcoma cell line, against target cells which express the relevant antigen (Embleton et al, 1983;Garnett et al, 1983).…”

Adjuvant Therapy in Gastrointestinal Carcinoma

“…The latter are tumor-specific antibodies developed in monoclonal hybridoma cell cultures and conjugated to known toxic agents. A number of antibody targetspecific agents are under trial for this pur pose, for example conjugates with vendesine [83], methotrexate and adriamycin [84], These few examples of tumor research prom ise not only new drugs or modification of old agents, but more sophisticated methods for their delivery. However, further meticulous investigation is required to examine existing and potential adjuvants and define those sub jects most suited to receive them.…”

Characterisation of a new murine B cell lymphoma

“…A number of research groups are examining closely the part that anti-idiotype antibodies may play in the therapy of lymphoma used alone , with attached drugs and toxins (Gilliland et al, 1980;Embleton et al, 1983), or carrying cellsterilising amounts of radionuclides (Larsen et al, 1983). In B cell lymphoma/leukaemia a major problem can arise in some patients from large quantities of circulating idiotype which can effectively block the entry of the therapeutic antibody into the tumour infiltrated tissues .…”